Format

Send to

Choose Destination
J Surg Oncol. 2018 Mar;117(4):579-587. doi: 10.1002/jso.24921. Epub 2018 Mar 12.

Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study.

Author information

1
Queensland Melanoma Project, Princess Alexandra Hospital, Brisbane, Australia.
2
Faculty of Medicine, The University of Queensland, Southern Clinical School, Princess Alexandra Hospital, Brisbane, Australia.
3
School of Medicine, Griffith University, Gold Coast, Australia.
4
School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.
5
School of Medicine and Public Health, The University of Newcastle, Newcastle, Australia.

Abstract

BACKGROUND:

Patients with in-transit melanoma metastases frequently experience high rates of recurrence, limited overall survival and reduced quality of life. After promising results within a Phase II, multi-center study, PV-10 treatment was continued at our institution for patients with in-transit disease.

METHODOLOGY:

An open-label, non-randomized, prospective study was performed at the Princess Alexandra Hospital, Queensland, Australia. Patients were treated with PV-10 in accordance with the treatment protocol established during a previous Phase II study. The primary outcome was the complete response of treated lesions.

RESULTS:

Forty-five patients were enrolled over a total of 82 treatment episodes from July 2008 to December 2015. With sequential PV-10 treatments the complete response rate was 42% and overall response rate 87% on an intention to treat analysis. The median follow-up duration was 22 months and the median overall survival was 25 months from first PV-10 treatment. Having fewer than 15 metastases at the time of treatment was associated with a complete response (P = 0.03).

CONCLUSIONS:

Intralesional PV-10 provided rapid lesion-specific ablation of melanoma metastases with well-tolerated local effects and minimal systemic adverse events. This therapy should be considered for patients with multiple accessible deposits within the spectrum of low to moderate disease volume.

KEYWORDS:

PV-10; Rose Bengal; in-transit; intralesional; melanoma; metastases

PMID:
29529343
DOI:
10.1002/jso.24921
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center